is conditional because patient preferences and the magnitude of previous response to methotrexate play an important role in this decision. Recommendations for treatment modification in patients treated with DMARDs who are not at target (Table 4 Treat-to-target A treat-to-target approach is strongly recommended over usual care for patients who have not been previously treated with bDMARDs or tsDMARDs This recommendation applies to dose optimization of methotrexate and to the subsequent addition